Friday, 20 Sep 2019

You are here

Hydroxychloroquine Underperforms in a Cutaneous Lupus Trial

Hydroxychloroquine has become a mainstay in the treatement of patients with systemic lupus erythematosus (SLE) with proven efficacy in managing many domains of lupus, including skin, joint, and other autoimmune features.

Arthritis & Rheumatology has published a a double-blind, randomized, placebo-controlled, parallel-group study of hydroxychloroquine (HCQ) in 103 patients with active cutaneous lupus (CLE) based on an inclusion Cutaneous Lupus Erythematosus Disease Area and Severity Index [CLASI] activity score of ≥4.

Patients received either HCQ or PBO in a 3:1 ratio for 16 weeks and then HCQ for the following 36-week single-blind period. The primary efficacy end point was a reduction in the CLASI activity score at week 16.

The CLASI score at week 16 was significantly improved in both the HCQ and the placebo groups; moreso in the HCQ group (CLASI change −4.6; 95% CI −6.1, −3.1) (P < 0.0001), than the PBO group (change −3.2; 95% CI −5.1, −1.3) (P = 0.002). Yet there was no significant between-group difference (P = 0.197).

Nonetheless, the physicians global assessment demonstrated a greater proportion of “improved” and “remarkably improved” patients in the HCQ group (51.4% versus 8.7%; P = 0.0002 between groups).  

While these results show the efficacy and tolerability of HCQ in patients with CLE, they are less than expected.  But there are several issues with this Japanese cohort that may explain these marginally effective results. First the patients were older (mean age >40 yrs), had long-standing chronic CLE, 36-46% were on background immunosuppressives (including tacrolimus and dapsone) and over half were active smokers.

Are these reflective of actual practices and real life experiences?  Study design and cohort inclusion will usually shape the outcomes of any trial and the clinical question it attempts to answer.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Sensitivity of Temporal Artery Biopsy

Metanalysis shows that temporal artery biopsy (TAB) for the diagnosis of giant cell arteritis (GCA) has a sensitivity of 77%, similar to results seen with temporal artery imaging. These data suggest clinicians may be willing to accept a GCA diagnosis without proof by TAB.

FDA Grants Breakthrough Status for Potential Lupus Nephritis Drug

Obinutuzumab (Gazyva) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for use in adults with lupus nephritis (LN). The drug made by Genentech, is going forward based on the Phase II NOBILITY study in adult patients with proliferative lupus nephritis (LN). Currently, there are no FDA-approved medicines for lupus nephritis.

Riociguat Fails in Systemic Sclerosis-Associated Digital Ulcers

Riociguat is an oral, selective soluble guanylate cyclase stimulator that has been studied in patients with digital ulcers (DU) due to systemic sclerosis (SSc) but study results show that short term (16 weeks) riociquat therapy does not sufficiently reduce the DU burden in SSc patients.

Nintedanib FDA Approved for Scleroderma Lung Disease

Last Friday, the US Food and Drug Administration approved Ofev (nintedanib) to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. ILD as a complication of SSc may lead to progressive loss of lung function and may be associated with a significant mortality risk. Prior to the approval of Olev, there were no FDA approved drugs for SSc-ILD.

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.